# Precision BioSciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/precision-biosciences

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.precisionbiosciences.com
- Total disclosed funding: $136M
- Latest round: Series B (May 25, 2018)
- Investors on record: 25

## About

Founded in 2006 by Jeff Smith and Derek Jantz and based in North Carolina, US, Precision BioSciences, Inc. is a biotechnology company initially focused on agricultural applications, which provides a genome editing platform called ARCUS for the treatment of genetic diseases and cancer. In March 2026, Precision BioSciences, Inc. raised USD 7.5 million in venture funding.


Precision BioSciences' platform ARCUS, leverages naturally occurring enzymes for precise DNA modifications. This platform, exemplified by I-CreI from algae, allows for specific DNA cuts to insert, remove, or repair genes in living cells and tissues with unparalleled accuracy. ARCUS technology has enabled the development of innovative treatments like PBGENE-HBV for chronic hepatitis B and PBGENE-PMM for mitochondrial myopathy. These programs aim to offer potential cures by targeting specific genetic mutations with high precision and efficacy. The platform is also used to genetically delete harmful genes, excise specific characteristics, correct mutated genes, and edit existing genes of plant sources for food production systems.

The company plans to utilize the 2024 funding to support R&D, meet working capital needs, and for general corporate purposes.

## Funding rounds

- Series B, May 25, 2018, $110M — Healthcare Royalty Partners, Alexandria Venture Investments, Amgen Ventures, Vivo Capital, OUP (Osage University Partners), F-Prime Capital, Adage Capital Management, Pontifax Venture Capital, Gilead Sciences, Inc., ArrowMark Partners, Leerink Partners, VenBio, RA Capital Management, Cormorant Asset Management, The Longevity Fund, Franklin Templeton, Cowen Investment Management, DUMAC, Brace Pharma Capital, OCV Partners, Agent Capital, Ridgeback Asset Management
- Series A, Apr 30, 2015, $26M — Amgen Ventures, Eight Roads Ventures, OUP (Osage University Partners), F-Prime Capital, Ziegler & Co., VenBio, Baxter Ventures, RA Capital Management, The Longevity Fund

## Investors

- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A, Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A, Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- Ziegler & Co. — Series A
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A, Series B
- Baxter Ventures (https://capitalatlas.ai/funds/baxter-ventures) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- The Longevity Fund (https://capitalatlas.ai/funds/the-longevity-fund) — Series A, Series B
- Healthcare Royalty Partners (https://capitalatlas.ai/funds/healthcare-royalty-partners) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- Adage Capital Management — Series B
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series B
- Gilead Sciences, Inc. — Series B
- ArrowMark Partners — Series B
- Leerink Partners — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series B
- Cowen Investment Management — Series B
- DUMAC — Series B
- Brace Pharma Capital (https://capitalatlas.ai/funds/brace-pharma-capital) — Series B
- OCV Partners (https://capitalatlas.ai/funds/ocv-partners) — Series B
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series B
- Ridgeback Asset Management — Series B